THE UNIVERSITY OF TENNESSEE
HEALTH SCIENCE CENTER.

Let's discuss a
RESEARCH STUDY INVESTIGATING CONJUNCTIVITIS

A Clinical Research (Observational) Study For Atopic Dermatitis (Eczema) Patients Experiencing Conjunctivitis (Pink Eye) While Taking Dupilumab

Why Me?

You may qualify to take part in a research study for those that are currently taking dupilumab and are experiencing the symptoms of conjunctivitis (pink eye).

REGENERON

THE UNIVERSITY OF TENNESSEE
HEALTH SCIENCE CENTER

What is the Research Study Investigating Conjunctivitis?

A research study to gather more information about patients that take dupilumab and experience a diagnosis of conjunctivitis (pink eye) is currently underway. The doctor would like to discuss this research study with you. You will discuss if:

- You have interest in taking part in a research study
- You are willing to be seen by the ophthalmologist taking part in the research study
- You can commit to a convenient appointment time with this ophthalmologist

Why is This Research Study Important?

In research studies some patients may be diagnosed with conjunctivitis while being treated with dupilumab. It is important to research why this is a common side effect. Assisting with this research would help to understand how and why this occurs. Having increased knowledge will help researchers better understand why conjunctivitis occurs in patients receiving dupilumab.

If you decide to take part in this study, you will be asked to schedule an appointment with an ophthalmologist (eye doctor taking part in this study) who is an expert in this field. If you are diagnosed with conjunctivitis, this ophthalmologist will treat you and follow up with you until your eye condition resolves.

If you are interested in scheduling an appointment with the research study ophthalmologist please call:

901-448-7375

A research study representative will connect you with the closest participating ophthalmologist office, so you can schedule your appointment right away.

Thank you for taking the time to consider this research study.

REGENERON